NO20010412L - Anvendelse av borreliacidal(e) epitoper av Borrelia burgdorferi ytre overflateprotein C som vaksine - Google Patents

Anvendelse av borreliacidal(e) epitoper av Borrelia burgdorferi ytre overflateprotein C som vaksine

Info

Publication number
NO20010412L
NO20010412L NO20010412A NO20010412A NO20010412L NO 20010412 L NO20010412 L NO 20010412L NO 20010412 A NO20010412 A NO 20010412A NO 20010412 A NO20010412 A NO 20010412A NO 20010412 L NO20010412 L NO 20010412L
Authority
NO
Norway
Prior art keywords
borrelia burgdorferi
borreliacidal
epitopes
vaccine
surface protein
Prior art date
Application number
NO20010412A
Other languages
English (en)
Other versions
NO329227B1 (no
NO20010412D0 (no
Inventor
Steven M Callister
Steven D Lovrich
Ronald F Schell
Dean A Jobe
Original Assignee
Gundersen Lutheran Medical Fou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gundersen Lutheran Medical Fou filed Critical Gundersen Lutheran Medical Fou
Publication of NO20010412D0 publication Critical patent/NO20010412D0/no
Publication of NO20010412L publication Critical patent/NO20010412L/no
Publication of NO329227B1 publication Critical patent/NO329227B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20010412A 1998-07-31 2001-01-24 Anvendelse av borreliacidal(e) epitoper av Borrelia burgdorferi ytre overflateprotein C som vaksine NO329227B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9495598P 1998-07-31 1998-07-31
PCT/US1999/017270 WO2000006745A1 (en) 1998-07-31 1999-07-30 Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine

Publications (3)

Publication Number Publication Date
NO20010412D0 NO20010412D0 (no) 2001-01-24
NO20010412L true NO20010412L (no) 2001-03-29
NO329227B1 NO329227B1 (no) 2010-09-20

Family

ID=22248146

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010412A NO329227B1 (no) 1998-07-31 2001-01-24 Anvendelse av borreliacidal(e) epitoper av Borrelia burgdorferi ytre overflateprotein C som vaksine

Country Status (13)

Country Link
US (2) US6210676B1 (no)
EP (1) EP1100922B1 (no)
JP (1) JP3631960B2 (no)
AT (1) ATE386805T1 (no)
AU (1) AU5328299A (no)
CA (1) CA2332570C (no)
CY (1) CY1107944T1 (no)
DE (1) DE69938183T2 (no)
DK (1) DK1100922T3 (no)
ES (1) ES2302385T3 (no)
NO (1) NO329227B1 (no)
PT (1) PT1100922E (no)
WO (1) WO2000006745A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) * 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US7060281B1 (en) 1999-06-18 2006-06-13 Research Foundation Of The State University Of New York Groups of barrelia burgdorferi and borrelia afzelii that cause lyme disease in humans
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
DE60131858T2 (de) * 2000-08-18 2008-12-04 The Research Foundation Of State University Of New York Borrelia burgdorferi rekombinante genkonstrukte
ES2298249T3 (es) * 2000-08-18 2008-05-16 Research Foundation Of State University Of New York Ospa modificada de borrelia burgdorferi.
EP1865062A3 (en) * 2000-08-18 2008-01-09 Research Foundation Of State University Of New York Altered OspA of Borrelia burgdorferi
US20020142355A1 (en) * 2000-11-14 2002-10-03 Baylor College Of Medicine Methods for the in vivo biotin labeling of polypeptides
MX2009004866A (es) * 2006-11-03 2009-05-19 Schering Plough Ltd Vacuna para enfermedad de lyme canina.
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2167537A2 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
US20110262475A1 (en) * 2008-05-02 2011-10-27 Earnhart Christopher G Lyme disease vaccine
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
JP2013539032A (ja) 2010-09-27 2013-10-17 コーネル ユニバーシティ ライム病の診断方法
BR112013009588A2 (pt) * 2010-10-20 2017-10-10 Univ Virginia Commonwealth vacinógeno ospc quimérico polivalente e antígeno para diagnóstico
US9562079B2 (en) 2012-04-18 2017-02-07 Zoetis Services Llc Vaccines and methods to treat lyme disease in dogs
UY34745A (es) 2012-04-18 2013-11-29 Zoetis Llc Vacunas y procedimientos para tratar la enfermedad de lyme en perros
US11061028B2 (en) 2014-09-24 2021-07-13 Defined Diagnostics, Llc Compositions and methods for the diagnosis of lyme disease
CA3082959A1 (en) 2017-12-04 2019-06-13 Intervet International B.V. Canine lyme disease vaccine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US5385826A (en) 1989-04-21 1995-01-31 Gundersen Medical Foundation, Ltd. Diagnostic assay for lyme disease
DE4015911A1 (de) 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
CA2077079A1 (en) 1990-03-07 1991-09-08 Thomas J. White Method for diagnosis of lyme disease
WO1992000055A1 (en) 1990-06-15 1992-01-09 Yale University Compositions and methods for the prevention and diagnosis of lyme disease
EP0701612B1 (en) 1993-04-29 1998-01-21 IMMUNO Aktiengesellschaft IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS
US5656451A (en) 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
EP0725838A4 (en) * 1993-10-26 1997-02-26 United Biomedical Inc STRUCTURED SYNTHETIC ANTIGAN BANKS AS DIAGNOSTICS, VACCINE AND THERAPEUTIC AGENTS
US5558993A (en) 1994-06-17 1996-09-24 The Regents Of The University Of California Cloned Borrelia burgdorferi virulence protein
US5853987A (en) 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
EP1019546B1 (en) 1996-03-26 2004-12-15 Cylex, Inc. Methods for measurement of lymphocyte function
EP0896583B1 (en) * 1996-05-02 2003-02-05 Dako A/S Use of peptide fragments derived from osp-c for diagnostic methods
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA

Also Published As

Publication number Publication date
CA2332570A1 (en) 2000-02-10
JP2002523019A (ja) 2002-07-30
EP1100922A1 (en) 2001-05-23
US6464985B1 (en) 2002-10-15
DE69938183D1 (de) 2008-04-03
JP3631960B2 (ja) 2005-03-23
DE69938183T2 (de) 2009-02-19
PT1100922E (pt) 2008-05-30
US6210676B1 (en) 2001-04-03
NO329227B1 (no) 2010-09-20
NO20010412D0 (no) 2001-01-24
DK1100922T3 (da) 2008-06-16
ATE386805T1 (de) 2008-03-15
ES2302385T3 (es) 2008-07-01
CY1107944T1 (el) 2013-09-04
AU5328299A (en) 2000-02-21
CA2332570C (en) 2009-12-08
EP1100922B1 (en) 2008-02-20
WO2000006745A1 (en) 2000-02-10

Similar Documents

Publication Publication Date Title
NO20010412D0 (no) Anvendelse av borreliacidal(e) epitoper av Borrelia burgdorferi ytre overflateprotein C som vaksine
EA200600905A1 (ru) АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
NO995458L (no) Humane 12-lignende reseptorproteiner, beslektede reagenser og metoder
DK0853487T3 (da) Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus
DE69922261D1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
WO2003078600A3 (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
WO1995014781A3 (en) Methods for diagnosing early lyme disease
WO2001064877A3 (en) Human schizophrenia gene
ATE353337T1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
WO2004020609A3 (en) Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
WO2001074904A3 (en) G-protein coupled receptors and nucleic acids encoding same
WO2003025147A3 (en) Novel polynucleotides and proteins encoded thereby
WO2000061754A3 (en) Human proteins and polynucleotides encoding them
WO2004058986A3 (en) Btl-ii nucleic acids, proteins, and antibodies
WO2001090187A3 (en) G-protein coupled olfactory receptors
WO2002040539A3 (en) Gpcr-like protein and nucleic acids encoding same
WO2001085989A8 (de) Hyphenspezifische faktoren aus candida albicans
WO2001074897A3 (en) Protein amf-1 to amf-10 and nucleic acids encoding the same
WO2002059313A3 (en) G-protein coupled receptors and nucleic acids encoding same
WO2002002637A3 (en) G-protein coupled receptors and nucleic acids encoding same
WO2002085924A3 (en) ANTI-α3(IV)NC1 MONOCLONAL ANTIBODIES AND ANIMAL MODEL FOR HUMAN ANTI-GLOMERULAR BASEMENT MEMBRANE AUTOANTIBODY DISEASE
WO2001064879A3 (en) G-proteins coupled receptor related polypeptides
Lachmann et al. Generation and preliminary characterisation of monoclonal antibodies directed to glycerophospholipid: cholesterol acyltransferase (GCAT) native epitopes of Aeromonas salmonicida
WO2001081378A3 (en) G-protein coupled receptors
WO2001088135A3 (en) G-protein coupled receptor proteins and nucleic acids encoding same

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees